https://www.selleckchem.com/pr....oducts/abbv-cls-484.
PURPOSE To report a case of reversible corneal endothelial abnormalities following treatment with netarsudil. OBSERVATION A 68-year-old woman presented with the complaint of blurred vision soon after starting treatment with the fixed dose combination of netarsudil and latanoprost (FC-netarsudil-latanoprost). She had been receiving the fixed dose combination of dorzolamide and timolol and latanoprost for primary open-angle glaucoma until her ophthalmologist switched latanoprost to FC-netarsudil-latanoprost 2 months before referral t
Like
Comment
Share
